Alkermes plc
ALKS
Rankning i aktier
#2585
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aktiekurs
$44.24
Marknadsvärde
$7.42B
Förändring (1 dag)
2.95%
Förändring (1 år)
42.79%
Land
IE
Handel Alkermes plc (ALKS)
Kategori
Healthcare
Intäkter för Alkermes plc (ALKS)
Intäkter i Jun 2026 TTM: $1.67B
Enligt Alkermes plc senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $1.67B. År 2023 hade företaget intäkter på $1.66B en ökning jämfört med intäkterna år 2022, som var $1.11B. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Alkermes plc från 2000 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | $1.67B | 7.06% |
| 2024 | $1.56B | -6.36% |
| 2023 | $1.66B | 49.61% |
| 2022 | $1.11B | -5.28% |
| 2021 | $1.17B | 13.00% |
| 2020 | $1.04B | -11.29% |
| 2019 | $1.17B | 7.01% |
| 2018 | $1.09B | 21.13% |
| 2017 | $903.37M | 21.15% |
| 2016 | $745.69M | 18.68% |
| 2015 | $628.34M | 1.54% |
| 2014 | $618.79M | 7.51% |
| 2013 | $575.55M | 0.00% |
| 2012 | $575.55M | 47.59% |
| 2011 | $389.98M | 108.95% |
| 2010 | $186.64M | 4.69% |
| 2009 | $178.28M | -45.45% |
| 2008 | $326.84M | 35.78% |
| 2007 | $240.72M | 0.31% |
| 2006 | $239.97M | 44.04% |
| 2005 | $166.60M | 118.85% |
| 2004 | $76.13M | 94.92% |
| 2003 | $39.05M | -17.37% |
| 2002 | $47.27M | -12.63% |
| 2001 | $54.10M | -3.44% |
| 2000 | $56.03M | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| $12.62B | 657.01% |
US
|
|
| $2.23B | 33.60% |
US
|
|
| $15.74B | 844.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 261.06% |
NL
|
